The global military drone market will grow from USD 15.80 billion in 2025 to USD 22.81 billion in 2030 at a CAGR of 7.6% during the forecast period according to a new report by MarketsandMarketstm.

Nervigesic 300mg Capsule is an antiepileptic medication. When given for epilepsy, it is believed to work by reducing the abnormal electrical activity in the brain, thus preventing seizures. It is also ...

The mental health trust for Cambridgeshire and Peterborough said it treated the patient for schizophrenia with the drug clozapine. They were being monitored via a so-called virtual ward ...

The U.S. Food and Drug Administration has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult ...

JSW MG Motor India has been working on diversifying its electric vehicle lineup for quite some time now. Also, the brand's Windsor EV has garnered impressive sales volume and has emerged as one of ...

Placed between the Essence and Essence Pro variants of the EV MG Windsor Exclusive Pro variants, it will come equipped with the bigger 52.9 kWh battery pack, offering a range of up to 449 km on a ...

Experts say there is low vaccine uptake and people are not accessing treatments. More than five years after the first cases of COVID-19 were detected in the United States, hundreds of people are ...

The novel PDE10A inhibitor CPL'36 offers a new mechanism of action and is both safe and effective for acute exacerbations of schizophrenia, new research suggests.

May 23 (Reuters) - International Paper (IP.N), opens new tab said on Friday it will close five packaging sites in Britain, cutting around 300 jobs, citing tough industry conditions. The U.S.-based ...

The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

Gerard Criner, MD, FACP, FACCP, MATINEE investigator, highlights trial results that showed reduced exacerbations and delayed disease progression in patients with eosinophilic chronic obstructive ...